IGI Logo

Alembic Pharmaceuticals is currently trading at Rs. 738.90, up by 3.20 points or 0.43% from its previous closing of Rs. 735.70 on the BSE.

The scrip opened at Rs. 736.10 and has touched a high and low of Rs. 743.00 and Rs. 728.20 respectively. So far 19676 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1107.80 on 30-Jun-2025 and a 52 week low of Rs. 635.30 on 23-Mar-2026.

Last one week high and low of the scrip stood at Rs. 836.00 and Rs. 706.85 respectively. The current market cap of the company is Rs. 14524.05 crore.

The promoters holding in the company stood at 69.74%, while Institutions and Non-Institutions held 20.43% and 9.83% respectively.

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Haloperidol Tablets, USP, 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Haldol Tablets, 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg, of Ortho McNeil Pharmaceutical (Ortho McNeil).

Haloperidol Tablets are indicated for: i) use in the management of manifestations of psychotic disorders and ii) the control of tics and vocal utterances of Tourette’s Disorder in children and adults.

Haloperidol Tablets, USP, 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg, have an estimated market size of $27 million for twelve months ending March 2026 according to IQVIA. The company has a cumulative total of 240 ANDA approvals (221 final approvals and 19 tentative approvals) from USFDA.